Juan Francisco Rodríguez-Moreno

Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.

Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Inmaculada Fernández et al. · Journal of Clinical Oncology · 2020 · 43 citations

Molecular Characterization, Urology, Surgical Oncology +15

PTEN expression and mutations in <i>TSC1</i>, <i>TSC2</i> and <i>MTOR</i> are associated with response to rapalogs in patients with renal cell carcinoma

Juan María Roldán‐Romero, Benoit Beuselinck, María Santos et al. · International Journal of Cancer · 2019 · 29 citations · Full text

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel <i>MTOR</i> -Activating Mutation

Juan Francisco Rodríguez-Moreno, María Apellániz-Ruiz, Juan María Roldán‐Romero et al. · Journal of the National Comprehensive Cancer Network · 2017 · 20 citations · Full text

Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients

María González‐Cao, Teresa Puértolas, Eva Muñoz‐Couselo et al. · 2020 · 19 citations · Full text

Immunology, Immunoediting, Pathology +20

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer

María Dolores Fenor, Sergio Ruiz‐Llorente, Juan Francisco Rodríguez-Moreno et al. · Clinical & Translational Oncology · 2022 · 18 citations

Urology, Mek Inhibitor Sensitivity, Medicine +5